Heron Therapeutics, Inc. /De/ (HRTX): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of HRTX were reported in the last 12 months. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Heron Therapeutics
From the latest filingsOverall: more buying than selling. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns HRTX
160 funds and institutions reported HRTX shares worth $57.7M at the end of Q2 2026, about 71% of the company. The largest holder is Rubric Capital Management LP with 15.9%.
Funds and institutions (13F) 71%Everyone else 29%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Rubric Capital Management LP | 30.05M | 15.87% | $12.8M | No change |
| Clearline Capital LP | 11.38M | 6.01% | $4.9M | -7% |
| BlackRock, Inc. | 10.55M | 5.57% | $4.5M | +4% |
| Velan Capital Investment Management LP | 8.75M | 4.62% | $3.7M | No change |
| Vanguard Capital Management LLC | 7.78M | 4.11% | $3.3M | -0% |
| Tejara Capital Ltd | 6.51M | 3.44% | $2.8M | +3% |
| Tang Capital Management LLC | 6.25M | 3.30% | $2.7M | No change |
| Geode Capital Management, LLC | 4.27M | 2.26% | $1.8M | +7% |
| Millennium Management LLC | 4.07M | 2.15% | $1.7M | -47% |
| JW Asset Management, LLC | 3.75M | 1.98% | $1.6M | No change |
| State Street Corp | 3.23M | 1.71% | $1.4M | -16% |
| UBS Group AG | 3.00M | 1.58% | $1.3M | +31% |
| Pale Fire Capital SE | 2.51M | 1.33% | $1.1M | -8% |
| Marshall Wace, LLP | 2.35M | 1.24% | $1M | – |
| Congress Park Capital LLC | 2.02M | 1.07% | $861K | -50% |
| Richmond Brothers, Inc. | 1.79M | 0.95% | $765K | +25% |
| Vanguard Portfolio Management LLC | 1.58M | 0.84% | $675K | +21% |
| AQR Capital Management LLC | 1.55M | 0.82% | $663K | +142% |
| Renaissance Technologies LLC | 1.51M | 0.80% | $643K | -12% |
| Vanguard Fiduciary Trust Co | 1.37M | 0.72% | $583K | +18% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No HRTX insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
HRTX short interest
High short interest. 17.9% of HRTX shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went down 14%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 34.00M HRTX shares were sold short, 17.9% of the shares outstanding, down 7.4% from the report before. At the average daily volume of 1.74M shares, buying them all back would take about 19.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 34.00M | 17.91% | -7% | 1.74M | 19.5 |
| Oct 15, 2026 | 36.74M | 19.35% | -20% | 2.58M | 14.2 |
| Sep 30, 2026 | 46.02M | 24.24% | +6% | 2.66M | 17.3 |
| Sep 15, 2026 | 43.38M | 22.85% | -3% | 1.56M | 27.8 |
| Aug 31, 2026 | 44.86M | 23.63% | -4% | 2.42M | 18.5 |
| Aug 14, 2026 | 46.74M | 24.62% | +8% | 3.79M | 12.3 |
| Jul 31, 2026 | 43.24M | 22.85% | +1% | 1.77M | 24.4 |
| Jul 15, 2026 | 42.63M | 22.52% | +5% | 3.19M | 13.3 |
| Jun 30, 2026 | 40.50M | 21.40% | -3% | 3.64M | 11.1 |
| Jun 15, 2026 | 41.88M | 22.12% | +4% | 6.25M | 6.7 |
| May 29, 2026 | 40.16M | 21.22% | +1% | 1.70M | 23.7 |
| May 15, 2026 | 39.68M | 20.96% | -3% | 2.83M | 14.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Heron Therapeutics company events
Heron Therapeutics filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership, listing). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Nov 9, 2026AgreementHeron Therapeutics, Inc., a Delaware corporation, and CorMedix Inc., a Delaware corporation, entered into an Asset Purchase Agreement, pursuant to which the Company has agreed to sell substantially all of its assets to the Buyer, other than certain excluded assets, including the Company’s federal… Filing
- Sep 29, 2026AgreementHeron Therapeutics, Inc., a Delaware corporation, entered into a multi-product Development and License Agreement with Long Grove Pharmaceuticals, LLC, a Delaware limited liability company, and Capstone Development Services Company, LLC, a Delaware limited liability company, which provided for… Filing
- Aug 14, 2026AgreementHeron Therapeutics, Inc. entered into Amendment No. 1 to Tax Benefit Preservation Plan, which amends the Tax Benefit Preservation Plan, dated as of August 14, 2025, by and between the Company and Computershare Trust Company, N.A., as rights agent. Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Jun 25, 2026ListingHeron Therapeutics, Inc. received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market, LLC notifying it that the closing bid price of the Company’s common shares over a period of thirty (30) consecutive trading days was below the minimum $1.00 per share… Filing
- Jun 16, 2026VoteReported shareholder vote results. Filing
- Jun 2, 2026AnnouncementAs previously disclosed, on December 11, 2023, Heron Therapeutics, Inc. received a Paragraph IV notice of certification from Slayback Pharma LLC (now owned by Azurity Pharmaceuticals, Inc.) advising that Slayback had submitted a new drug application under Section 505(b)(2) of the Federal Food… Filing
- May 11, 2026ResultsReleased financial results. Filing
- Apr 6, 2026LeadershipHeron Therapeutics, Inc. and Craig Collard, the Company’s Chief Executive Officer, entered into an amendment and restatement of that certain Employment Agreement, dated as of April 3, 2023 (as amended, the “Collard Agreement”), in order to amend certain terms relating to the termination of Mr.… Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 9, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Heron Therapeutics financials
Famous investors that hold HRTX
4 of the 50 well-known investors we track reported holding HRTX in their latest 13F filing. The largest position is Jim Simons's, worth $492K.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.57M | $492K | 0.0% | +4% |
| Israel Englander · Millennium Management | Q3 2026 | 1.46M | $458K | 0.0% | -64% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 477,208 | $150K | 0.0% | New |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 94,864 | $29.7K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Heron Therapeutics, Inc. /De/ (HRTX) stock
Who owns the most HRTX stock?
The largest reported owner of Heron Therapeutics, Inc. /De/ (HRTX) is Rubric Capital Management LP, with 15.9% of the company. In total, 160 funds and institutions reported holding HRTX at the end of Q2 2026, together about 71% of the shares. See the largest owners.
Are HRTX insiders buying or selling?
No HRTX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in HRTX?
As of Oct 30, 2026, 34.00M HRTX shares were sold short, 17.9% of the shares outstanding, down 7.4% from the report before. At the average daily volume of 1.74M shares, buying them all back would take about 19.5 trading days (days to cover). See the history.
Which famous investors hold HRTX?
4 of the 50 well-known investors we track reported HRTX in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $492K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.